Osmotica Pharmaceuticals plc to Provide First Quarter 2021 Business and Financial Update on May 13, 2021
Osmotica Pharmaceuticals (Nasdaq: OSMT) is set to announce its first quarter 2021 financial results on May 13, 2021, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Osmotica Pharmaceuticals (Nasdaq: OSMT) is set to announce its first quarter 2021 financial results on May 13, 2021, after U.S. market close. CEO Brian Markison, COO JD Schaub, and CFO Andrew Einhorn will conduct a conference call at 4:30 p.m. ET. Investors can access the call via a toll-free number or through the company's website for a live and replay webcast. Osmotica specializes in biopharmaceuticals aimed at underserved patient populations, with operations in the U.S., Argentina, and Hungary.
Positive
- Upcoming financial results announcement may provide insights into company performance.
- CEO and executive team engagement through a conference call enhances transparency.
Negative
- None.
Details
News Market Reaction – OSMT
The recorded move for OSMT in the trading session of this news was +2.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 first quarter financial results on Thursday, May 13, 2021, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
| Date | Thursday, May 13, 2021 |
| Time | 4:30 p.m. ET |
| Toll free (U.S.) | (866) 672-5029 |
| International | (409) 217-8312 |
| Conference ID | 6588774 |
| Webcast (live and replay) | www.osmotica.com under the “Investor & News” section |
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.